Skip to main content
Erschienen in: Annals of Surgical Oncology 8/2010

01.08.2010 | Healthcare Policy and Outcomes

Adherence to the National Quality Forum (NQF) Breast Cancer Measures Within Cancer Clinical Trials: A Review From ACOSOG Z0010

verfasst von: Lee G. Wilke, MD, Karla V. Ballman, PhD, Linda M. McCall, MS, Armando E. Giuliano, MD, Pat W. Whitworth, MD, Peter W. Blumencranz, MD, Douglas S. Reintgen, MD, William E. Burak, MD, A. Marilyn Leitch, MD, Kelly K. Hunt, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 8/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

In 2007, the National Quality Forum (NQF) released four performance measures for the treatment of breast cancer. We proposed to study the degree of adherence with these measures among participating institutions in a multi-institutional trial.

Methods

American College of Surgeons Oncology Group (ACOSOG) Z0010 enrolled breast cancer patients onto a phase II trial studying the prognostic significance of bone marrow and sentinel node micrometastases. The current study used χ2 analyses to determine the degree of adherence with four NQF measures among three institution types: academic, community, and teaching affiliate.

Results

The study revealed small but important differences in two measures. Ninety-five percent of patients from teaching affiliated institutions received whole-breast radiation compared to 92% at academic and 91% at community hospitals. Among patients who were underinsured or uninsured, a marked decrease in radiation use was noted in comparison to patients with insurance—85 versus 93%, respectively. The study also revealed a difference among institutional types in patients undergoing excisional biopsy for diagnosis. In teaching-affiliated hospitals, 28.6% underwent excisional biopsy as compared to 36.8 and 37.4% in academic and community hospitals, respectively. There was no statistically significant difference between adherence rates with the remaining two measures. Adjuvant chemotherapy was administered to patients with hormone receptor negative tumors ≥1 cm in size in 79–85% of institutions. Tamoxifen was administered to 79–82% of those patients with hormone receptor–positive cancers.

Conclusions

Among breast cancer patients enrolled onto a multi-institutional clinical trial, we found a high degree of adherence with current consensus standards for adjuvant treatment, despite varied practice environments.
Literatur
5.
Zurück zum Zitat Hassett MJ, Hughes ME, Niland JC, et al. Selecting high priority quality measures for breast cancer quality improvement. Med Care. 2008;46:762–70.CrossRefPubMed Hassett MJ, Hughes ME, Niland JC, et al. Selecting high priority quality measures for breast cancer quality improvement. Med Care. 2008;46:762–70.CrossRefPubMed
7.
Zurück zum Zitat Cheng SH, Wang CJ, Lin JL, Horng CF, Lu MC, Asch SM, et al. Adherence to quality indicators and survival in patients with breast cancer. Med Care. 2009;47:217–25.CrossRefPubMed Cheng SH, Wang CJ, Lin JL, Horng CF, Lu MC, Asch SM, et al. Adherence to quality indicators and survival in patients with breast cancer. Med Care. 2009;47:217–25.CrossRefPubMed
8.
Zurück zum Zitat Schacter AM, Mamaladze V, Lewin G, Graham ID, Brouwers M, Sampson M, et al. Many quality measurements, but few quality measures assessing the quality of breast cancer care in women: a systematic review. BMC Cancer. 2006;6:291. Schacter AM, Mamaladze V, Lewin G, Graham ID, Brouwers M, Sampson M, et al. Many quality measurements, but few quality measures assessing the quality of breast cancer care in women: a systematic review. BMC Cancer. 2006;6:291.
9.
Zurück zum Zitat Brucker SY, Schumacher C, Sohn C, Rezai M, Bamberg M, Wallwiener D. (2008) Steering Committee. Benchmarking the quality of breast cancer care in a nationwide voluntary system: the first five-year results (2003–2007) from Germany as a proof of concept. BMC Cancer. 8:358.CrossRefPubMed Brucker SY, Schumacher C, Sohn C, Rezai M, Bamberg M, Wallwiener D. (2008) Steering Committee. Benchmarking the quality of breast cancer care in a nationwide voluntary system: the first five-year results (2003–2007) from Germany as a proof of concept. BMC Cancer. 8:358.CrossRefPubMed
10.
Zurück zum Zitat Mandelblatt JS, Potosky AL. On the road to improving the quality of breast cancer care: a distance still to travel. Med Care. 2008;46:759–61.CrossRefPubMed Mandelblatt JS, Potosky AL. On the road to improving the quality of breast cancer care: a distance still to travel. Med Care. 2008;46:759–61.CrossRefPubMed
11.
Zurück zum Zitat Malin JL, Schneider EC, Epstein AM, et al. Results of the National Initiative for Cancer Care Quality. How can we improve the quality of cancer care in the United States? J Clin Oncol. 2006;24:626–33.CrossRefPubMed Malin JL, Schneider EC, Epstein AM, et al. Results of the National Initiative for Cancer Care Quality. How can we improve the quality of cancer care in the United States? J Clin Oncol. 2006;24:626–33.CrossRefPubMed
12.
Zurück zum Zitat Desch CE, McNiff KK, Schneider EC, et al. American Society of Clinical Oncology/National Comprehensive Cancer Network quality measures. J Clin Oncol. 2008;26:3631–7.CrossRefPubMed Desch CE, McNiff KK, Schneider EC, et al. American Society of Clinical Oncology/National Comprehensive Cancer Network quality measures. J Clin Oncol. 2008;26:3631–7.CrossRefPubMed
14.
Zurück zum Zitat Wilke LG, McCall LM, Posther KE, et al. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol. 2006;13:491–500.CrossRefPubMed Wilke LG, McCall LM, Posther KE, et al. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol. 2006;13:491–500.CrossRefPubMed
15.
Zurück zum Zitat Leitch AM, Beitsch PD, McCall LM, et al. Patterns of participation and successful patient recruitment to American College of Surgeons Oncology Group Z0010, a phase II trial for patients with early-stage breast cancer. Am J Surg. 2005;190:539–42.CrossRefPubMed Leitch AM, Beitsch PD, McCall LM, et al. Patterns of participation and successful patient recruitment to American College of Surgeons Oncology Group Z0010, a phase II trial for patients with early-stage breast cancer. Am J Surg. 2005;190:539–42.CrossRefPubMed
16.
Zurück zum Zitat Posther KE, McCall LM, Blumencranz PW, et al. Sentinel node skills verification and surgeon performance: data from a multicenter clinical trial for early-stage breast cancer. Ann Surg. 2005;242:593–9.PubMed Posther KE, McCall LM, Blumencranz PW, et al. Sentinel node skills verification and surgeon performance: data from a multicenter clinical trial for early-stage breast cancer. Ann Surg. 2005;242:593–9.PubMed
18.
Zurück zum Zitat Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233–41.CrossRefPubMed Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233–41.CrossRefPubMed
19.
Zurück zum Zitat Veronesi U, Cascinelli N, Mariani L. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347:1227–32.CrossRefPubMed Veronesi U, Cascinelli N, Mariani L. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347:1227–32.CrossRefPubMed
20.
Zurück zum Zitat Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;365:1687–717.CrossRef Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;365:1687–717.CrossRef
21.
Zurück zum Zitat Smith BD, Smith GL, Roberts KB, et al. Baseline utilization of breast radiotherapy before institution of the Medicare practice quality reporting initiative. Int J Radiat Oncol Biol Phys. 2009;74:1506–12.PubMed Smith BD, Smith GL, Roberts KB, et al. Baseline utilization of breast radiotherapy before institution of the Medicare practice quality reporting initiative. Int J Radiat Oncol Biol Phys. 2009;74:1506–12.PubMed
22.
Zurück zum Zitat Buchholz TA, Theriault RL, Niland JC, et al. The use of radiation as a component of breast conservation therapy in National Comprehensive Cancer Network centers. J Clin Oncol. 2006;24:361–9.CrossRefPubMed Buchholz TA, Theriault RL, Niland JC, et al. The use of radiation as a component of breast conservation therapy in National Comprehensive Cancer Network centers. J Clin Oncol. 2006;24:361–9.CrossRefPubMed
Metadaten
Titel
Adherence to the National Quality Forum (NQF) Breast Cancer Measures Within Cancer Clinical Trials: A Review From ACOSOG Z0010
verfasst von
Lee G. Wilke, MD
Karla V. Ballman, PhD
Linda M. McCall, MS
Armando E. Giuliano, MD
Pat W. Whitworth, MD
Peter W. Blumencranz, MD
Douglas S. Reintgen, MD
William E. Burak, MD
A. Marilyn Leitch, MD
Kelly K. Hunt, MD
Publikationsdatum
01.08.2010
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 8/2010
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-010-0980-9

Weitere Artikel der Ausgabe 8/2010

Annals of Surgical Oncology 8/2010 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.